episil is a patented oral spray indicated for local treatment of pain related to oral mucositis.
The tie up allows Teva to commercialize episil in Germany, Spain, Poland, Switzerland and the Czech Republic.
Teva expects to launch episil in the final quarter of 2011.
Sinclair IS CEO Chris Spooner said eisil is a cornerstone of their supportive oncology portfolio and they look forward to working with Teva as we drive sales of this product.